Advertisement

Reactions Weekly

, Volume 1737, Issue 1, pp 37–37 | Cite as

Antineoplastic

Clonal evolution of Philadelphia chromosome in acute myeloid leukemia: case report
Case report
  • 49 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A 62-year-old woman experienced clonal evolution of Philadelphia chromosome during treatment with cytarabine, cladribine, unspecified granulocyte colony stimulating factors and azacitidine for acute myeloid leukaemia [AML; not all routes and dosages stated].

The woman presented with significant joint pain and myalgia over a period of 5 months. Laboratory tests were consistent with a diagnosis of AML. Cytogenetic testing showed a normal female karyotype with normal FISH for AML/myelodysplastic syndrome. Flow cytometry revealed 27% aberrant myeloblasts expressing CD34, CD117, CD71, HLA-DR, CD13, dim CD33 along with positive myeloperoxidase. Subsequently, she started receiving continuous IV infusion of cytarabine 100 mg/m2days 1−7 and idarubicin. She achieved a complete remission...

Reference

  1. Yogarajah M, et al. Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment. Leukemia and Lymphoma 59: 3010-3012, No. 12, 2 Dec 2018. Available from: URL: http://doi.org/10.1080/10428194.2018.1459614 - USACrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations